ProQR Therapeutics N.V. (PRQR)
PRQR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/0001104659-26-026713-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | PRQR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | 2014 |
| SEC CIK | 0001612940 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | P7 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.8M |
| Net income | -$47.2M |
| Operating income | Not in SEC XBRL data |
| Net margin | -265.2% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.7× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-15 |
| Latest annual report | 20-F | 2026-03-12 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-09-23 |
Source: SEC EDGAR submissions feed, 389 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics Inc. | $0.7700 | -2.56% | $213.4M |
| EVMN | Evommune Inc. | $5.88 | -2.81% | $213.4M |
| CAMP | CAMP4 Therapeutics Corporation | $3.43 | -6.28% | $215.2M |
| ADCT | ADC Therapeutics SA Common Shares | $1.70 | -8.60% | $217.0M |
| MGNX | MacroGenics Inc. | $3.42 | -8.06% | $217.9M |
| RNAC | Cartesian Therapeutics Inc. | $6.57 | -6.01% | $198.8M |
| SION | Sionna Therapeutics Inc. | $4.38 | -6.61% | $198.0M |
| PYXS | Pyxis Oncology Inc. | $1.85 | -7.96% | $221.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier